

**GENAISSANCE
PHARMACEUTICALS****RECEIVED
CENTRAL FAX CENTER**

OCT 13 2004

FIVE SCIENCE PARK
NEW HAVEN, CT 06511
TEL 203.773.1450
FAX 203.562.9377
WWW.GENAISSANCE.COM**To: Commissioner for Patents****Fax Number: 703.872.9306****Date: October 13, 2004****From: Matthew M. Catlett****Company: U.S. Patent & Trademark Office****Subject: US Appl. No. 09/856,803****Pages: 6 (including cover sheet)****Please see attached.**

The document(s) accompanying this facsimile may contain information from Genaissance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that Genaissance may arrange for the return of the original document(s) at no cost to you.

**RECEIVED
CENTRAL FAX CENTER**

Docket No. MWH-0029US

OCT 13 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stephen B. Liggett
Application No.: 09/856,803
Filed: May 25, 2001 (35 U.S.C. § 371 of PCT/US99/27963, filed November 24, 1999, which claims benefit of U.S. Appl. No. 60/109,886, filed November 25, 1998)
Confirmation No.: 3706
Group No.: 1634
Examiner: Myers, C.
For: **POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE β_2 -ADRENERGIC RECEPTOR**

Commissioner for Patents

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on October 13, 2004


Matthew M. Catlett**RESPONSE TO FINAL OFFICE ACTION**

In response to the Final Office Action dated July 30, 2004 regarding the above-captioned application, please amend the application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.